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Worldwide variation in the distribution of BRCA1 and BRCA2 mutations is well recognised, and for the Belgian population no
comprehensive studies about BRCA1/2 mutation spectra or frequencies have been published. We screened the complete coding
region of both genes in 451 individuals from 349 Belgian families referred to a family cancer clinic and identified 49 families with a
BRCA1 and 26 families with a BRCA2 mutation. Six major recurrent mutations (BRCA1 IVS5þ3A4G, 2478–2479insG, E1221X and
BRCA2 IVS6þ1G4A, 6503-6504delTT, 9132delC) accounted for nearly 60% of all mutations identified. Besides 75 true pathogenic
mutations, we identified several variants of unknown clinical significance. In combination with a family history, an early average age of
female breast cancer diagnosis (Po0.001), and the presence of a relative with ovarian cancer (Po0.0001) or multiple primary breast
cancers (P¼0.002), increased the chance for finding a mutation. Male breast cancer was indicative of a BRCA2 mutation segregating
in the family (P¼0.002). Mutations in the 50-end of BRCA1 and BRCA2 were associated with a significantly increased risk for ovarian
cancer relative to the central portion of the gene. Our study suggests a role for additional breast cancer susceptibility genes in the
Belgian population, since mutation detection ratios were low in high-risk breast cancer-only families as compared to breast–ovarian
cancer families. Given the large proportion of recurring mutations, molecular testing can now be organised in a more cost-effective
way. Our data allow optimisation of genetic counselling and disease prevention in Belgian breast/ovarian cancer families.
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Since the mapping and the cloning of two genes that confer
susceptibility to both breast and ovarian cancer, BRCA1 and
BRCA2 (Miki et al, 1994; Wooster et al, 1995; Tavtigian et al, 1996),
it became possible to offer genetic testing to families with a
predisposition for breast and/or ovarian cancer. Consequently,
individuals at risk can now be identified as candidates for
surveillance programmes. A large number of distinct mutations
in the BRCA1 and BRCA2 genes have been reported worldwide, but
population-specific variation in the distribution of BRCA1/2
mutations is well recognised. In some populations or ethnic
groups, founder mutations form a sufficient proportion of the total
to justify the adoption of specific molecular screening strategies.
To date, no comprehensive studies in the Belgian population
have been published. Only data from small series are available
(Claes et al, 1999a,b) or from studies in which the analysis was
restricted to a few BRCA1/2 exons or to BRCA1 only (Peelen et al,
1997; Sibille-Hoang et al, 1998; Goelen et al, 1999). We performed
mutation screening of the complete coding region of BRCA1 and
BRCA2 in 349 unrelated Belgian families referred to our family
cancer clinic and report here the nature and distribution of the
mutations identified. We found phenotypic differences between
families in whom a disease-causing mutation was identified vs
BRCA1/2 mutation-negative families. We also evaluated in our
cohort of patients if we could find an association between mutation
site and relative risk of breast or ovarian cancer.
MATERIALS AND METHODS
Study population
Breast and/or ovarian cancer-prone families visiting the Centre for
Medical Genetics at the Ghent University Hospital were selected
for molecular testing of the BRCA1/2 genes if fulfilling one of the
following inclusion criteria:
1. families with at least three first-degree relatives(*) with breast
and/or ovarian cancer;
2. families with at least two first- and/or second-degree rela-
tives(*) with breast and/or ovarian cancer before an average age
of 50 years;
3. sporadic patients diagnosed with breast or ovarian cancer
before the age of 38 years;
4. sporadic patients diagnosed with multiple primary breast
cancers or concomitant breast and ovarian cancer and all
tumours occurred before an average age of 50 years; and
5. sporadic patients with male breast cancer
(*) in case of male gene transmission, two affected females
related through a male were considered to be first-degree relatives.
Counselling and genetic testing were provided by a multi-
disciplinary team of genetic counsellors, gynaecologists, oncolo-
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sTable 1 Unclassified variants in BRCA1 and BRCA2
Exon/
intron Nucleotide change
Amino-acid
change BIC
No. of
families Type of family
Polarity
change
Conserved in
dog/mouse/
rat/chicken Pathogenic status
BRCA1
2 IVS2–14C4T Noncoding Y 1 F, brca only / / UV/P (no aberrant transcript
observed by cDNA analysis)
Claes et al (2003)
10 IVS10+8C4T Noncoding N 1 Sporadic / / UV/P (no aberrant transcript
observed by cDNA analysis)
11 2196G4A D693N Y 3 F, brca-only
a F, brovca; H,
brca only
N (negatively
charged-
uncharged polar)
N/N/N/N UV/P (in two of the families
true pathogenic BRCA2
mutations (IVS6+1G4A,
1617–1618delAG) were
segregating)
11 3238G4A S1040N Y 3 H, brca-only
a F, brovca; F,
brca only
n N/Y/Y/N UV/P [in two of the families
pathogenic mutations were
segregating (BRCA1 E1221X,
BRCA2 1617–618delAG)]
11 3298A4C E1060A Y 5 Sporadic
a F, brca-only; F,
brovc
a H, brca only
N (negatively
charged-
positively
charged)
Y/Y/Y/N UV/P (variant in linkage
disequilibrium with BRCA1
E1221X)
11
b 4145A4C S1342S N 1 H, brca only / / UV
17 5112G4A V1665M Y 1 H, brca only N Y/Y/Y/Y UV/P (not segregating with the
disease)
BRCA2
3 407A4G N60S Y 1 F, brca only N Y/N/N/N UV
4 IVS4+33A4G Noncoding N 1 F, brovca / / UV/P (patient is carrying a
pathogenic mutation (BRCA1
Q1281X); no aberrant
transcript observed by cDNA
analysis)
10 1022–5insT Noncoding N 1 H, brovca / / UV/P (no aberrant transcript
observed by cDNA analysis)
Claes et al (2003)
10
b 1441G4A G405R N 1 H, brca only Y Y/N/Y/N UV
10 1571G4A R448H Y 1 F, brca only N N/N/N/N UV
10 1613A4G E462G Y 1 F, brca only Y Y/Y/Y/Y UV
11 3199A4G N991D Y 2 H, brca-only F, brovca Y N/N/N/N UV/P (in one of the families
BRCA1 5382insC was
segregating and the patient
was homozygous for N991D)
11 7052A4G E2275G N 1 F, brca only, male brca Y Y/N/N/Y UV/P (variant cosegregating
with BRCA2 9132delC in one
of the families)
14 7285G4C G2353R Y 1 F, brovca Y Y/N/N/N UV
14 7641A4G T2471T N 1 H, brca only / / UV (identified in two sisters
with brca)
15 7691G4A R2488K Y 2 H, brca only N Y/Y/Y/Y UV/P (in one family not
segregating with the disease;
variant in linkage disequilibrium
with 2166C4T (S646S))
15 7830G4C A2534A N 1 Sporadic / / UV/P
17 8172C4T S2648S N 1 Sporadic / / UV/P
18 8395C4G D2723H Y 1 H, brca only N (negatively
charged-
positively
charged)
Y/Y/Y/Y UV
18 8471G4A G2748D Y 1 F, brca only; Y Y/Y/Y/Y UV
20 8795A4C E2856A Y 3 F, brca-only; H, brca-only
sporadic
Y Y/Y/Y/Y UV (not segregating with the
disease in one of the families)
22 9078G4T K2950N Y 1 F, brca only N (positively
charged-
uncharged polar)
Y/Y/Y/Y UV (identified in two sisters
with brca, one of them
carrying a truncating BRCA1
mutation)
23 9266C4T T3013I Y 1 F, brca only Y N/N/N/Y UV
25 9520T4C Y3098H Y 1 F, brca only N (positively
charged-
uncharged polar)
N/N/N/Y UV
25 IVS25+9A4C Noncoding Y 1 H, brovca / / UV/P (identified in patient
carrying a BRCA1 mutation; no
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sgists, a psychologist and molecular biologists (De Vos et al, 1999).
Before taking a blood sample, an informed consent was obtained.
This study was approved by the ethics committee of the Ghent
University Hospital.
In total, 58 sporadic patients (without a family history) and 291
families with a history of breast and/or ovarian cancer were
analysed. To investigate familial clustering of the disease, we made
a distinction between families with hereditary breast and/or
ovarian cancer (HBOC) and familial breast and/or ovarian cancer
(FBOC). Hereditary breast and/or ovarian cancer families are at
high risk (43 times population risk) and defined as families with
at least three first-degree relatives with breast and/or ovarian
cancer (or second-degree relatives in case of paternal inheritance)
in at least two successive generations and at least one of them
diagnosed before the age of 50 years. Families with at least two
first-degree relatives (or second-degree relatives, in case of
paternal inheritance) with breast and/or ovarian cancer diagnosed
at young age, but not fulfilling the criteria for HBOC, are FBOC
families. These families are at moderate increased risk (two to
three times population risk). In total, we analysed 91 HBOC
families and 200 FBOC families (Table 1).
When feasible, we investigated multiple affected family members
in order to exclude the presence of a phenocopy. In total, 451
individuals from 349 families were selected for genetic testing (i.e.
on average 1.29 individuals per family). For most patients, clinical
files and pathological records were retrieved and re-evaluated. In
22 families, no affected relative was available for testing for various
reasons (11 breast cancer-only families (10 FBOC and one HBOC)
and 11 breast–ovarian cancer families (nine FBOC and two
HBOC)), and in these families, 28 asymptomatic first-degree
relatives of breast/ovarian cancer patients were analysed. Further-
more, two asymptomatic women were analysed whose mothers
had died of a breast cancer diagnosed before the age of 35 years,
but without a further family history.
Mutation detection
We screened the complete coding region of BRCA1 and BRCA2 in
all families. For the first 85 families, the following strategy was
used: in the first instance, BRCA1 exon 11 and BRCA2 exons 10
and 11 were analysed with the protein truncation test (PTT)
(Hogervorst et al, 1995; Friedman et al, 1997). If no mutation was
found, all other exons and splice sites of BRCA1 were investigated
by heteroduplex analysis (HA) as described (Claes et al, 1999a). In
68 families in whom no mutations were identified, HA for all
remaining coding exons of BRCA2 was performed.
For 203 families, we applied another strategy. BRCA1 exon 11
and BRCA2 exon 11 were investigated by PTT and all remaining
coding exons and splice sites with denaturing gradient gel
electrophoresis (DGGE) (van der Hout et al, 1999), a more
sensitive technique than HA. The PCR set-up was automated using
a robot (RoboAmp 4200, MWG Biotech, Ebersberg, Germany).
As PTT only allows the detection of truncating mutations, direct
sequencing of BRCA1 exon 11 and BRCA2 exon 11 was performed
for the last 62 families using the dye terminator chemistry on the
ABI3100. All remaining coding exons and splice sites were
investigated with DGGE.
When a mobility shift was observed on HA, PTT or DGGE gels,
cycle sequencing was performed using dye primer chemistry on
the ALF Express (Amersham Biosciences, Buckinghamshire,
England) or dye terminator chemistry on the ABI377 or ABI3100
(Applied Biosystems, Foster City, USA) according to the manu-
facturer’s instructions.
Furthermore, a specifically designed PCR assay was used to
screen all families for four recurrent BRCA1 rearrangements
(deletion exon 22, deletion exon 13, duplication of exon 13,
deletion exons 8–9) (Petrij-Bosch et al, 1997; Puget et al, 1999;
Rohlfs et al, 2000). Recently, multiplex ligation-dependent probe
amplification (MLPA), a sensitive and comprehensive high-
throughput test to detect single or multiple exon deletions and
amplifications in the BRCA1 gene, has been made commercially
available by MRC-Holland. We analysed with MLPA 117 families
in whom no mutation was identified by conventional PCR-based
techniques (all 55 remaining HBOC, 52 FBOC and 10 sporadic
patients).
All mutations were reconfirmed on a second blood sample from
the index case before offering counselling and access to genetic
testing for at-risk adult family members.
Statistical analysis
The SPSS version 11.01 statistical analysis program was used for all
analyses. The analyses were used to describe the specific
characteristics (phenotypes) of the families. Characteristics
included the following: at least one family member diagnosed
with ovarian cancer, with bilateral breast cancer/multiple ipsilat-
eral primary breast cancers, with male breast cancer or with both
breast and ovarian cancer. These cancer diagnosis descriptors were
analysed as dichotomous variables (presence vs absence) with the
two-sided w
2 test and Fisher’s exact test. Independent samples T-
test was used to evaluate continuous variables, such as the mean
age at diagnosis of breast cancer and ovarian cancer and average
number of breast/ovarian cancers, between families carrying each
genotype (BRCA1, BRCA2, either mutation, neither mutation). All
statistical tests were two-sided. P-values less than 0.05 were
considered to be statistically significant.
aberrant transcript observed
at cDNA level) Claes et al
(2003)
27 10338G4A R3370R Y 1 H, brca only / / UV/P (identified in a patient
carrying BRCA2 Y42C)
27 10462A4G I3412V Y 1 F, brca only N N/N/N/N UV/P (not segregating with the
disease in the family)
H¼hereditary breast cancer; F¼familial breast cancer; brca¼breast cancer; ovca¼ovarian cancer; Brca-only¼site-specific breast cancer family; brovca¼breast cancer family
with at least one case of ovarian cancer; UV¼unclassified variant; P¼polymorphism; Y¼yes; N¼no.
aIn this family two UVs were identified (BRCA1 S1040N and D693N) and
one pathogenic mutation (BRCA2 1617–1618delAG).
bTwo genetic variants identified in the same patient.
Table 1 Continued
Exon/
intron Nucleotide change
Amino-acid
change BIC
No. of
families Type of family
Polarity
change
Conserved in
dog/mouse/
rat/chicken Pathogenic status
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BRCA1 and BRCA2 mutations
In total, 49 (18 distinct) BRCA1 mutations and 26 (10 distinct)
BRCA2 mutations were identified (Figure 1). The vast majority of
the mutations are predicted to lead to a premature stop codon (39
frameshifts, 15 nonsense mutations and 24 splice site disruptions).
Nontruncating amino-acid substitutions occurring in only a
limited number of families were considered as unclassified variants
(Table 1). For the statistical analyses, these families were
considered as BRCA1/2 mutation negative. Only BRCA2 Y42C
was thought to be a pathogenic mutation. Y42 is a highly
conserved amino acid and Y to C is a radical amino-acid change,
compromising in vivo the interaction between BRCA2 and
replication protein A (Wong et al, 2003).
All splice site mutations were studied at the RNA level (Claes
et al, 2002; Claes et al, 2003). RT–PCR analysis for BRCA2 R2336H
in the last codon of exon 13 was not yet described and revealed the
wild-type allele and three smaller transcripts, representing a
complete loss of exon 13, loss of exon 12 and loss of exons 12 and
13. Loss of exon 12 was also observed in transcripts from normal
individuals (Figure 2).
The large majority of the mutations (480%) were recurrent.
BRCA1 IVS5þ3A4G and BRCA2 IVS6þ1G4A, respectively,
represent the most frequent mutations in BRCA1 and BRCA2.
BRCA1 IVS5þ3A4G is a Belgian founder mutation (Claes et al,
1999b). For BRCA2 IVS6þ1G4A haplotypes could not be
established since only one carrier per family was available for
study. A founder effect is very likely since this mutation has not yet
been reported in other populations, and the donor site of BRCA2
exon 6 does not represent a mutational hotspot region given the
limited number of mutations reported in the BIC database in this
region. The recurrence of the other mutations was also due to
founder effects (data not shown).
In some populations, large intragenic deletions/duplications
constitute a substantial fraction of mutations (Hogervorst et al,
2003; Montagna et al, 2003). We investigated the prevalence of
single or multi-exon deletions/duplications in our Belgian study
population. Therefore, we analysed with MLPA 117 families in
whom no mutation was identified by conventional PCR-based
techniques (all 55 remaining uninformative HBOC families, 52
FBOC families and 10 sporadic patients). In none of them a
genomic rearrangement was detected.
Clinical characteristics indicative of a germline mutation
In patients with a family history of breast/ovarian cancer,
significantly more mutations were identified compared to sporadic
Figure 1 Diagrammatic representation of BRCA1 and BRCA2 exons, showing 49 BRCA1 and 26 BRCA2 germline mutations identified in Belgian breast/
ovarian cancer families selected for genetic testing. A correlation with the phenotype in each mutation-positive family was made based on the ratio of
ovarian cancer cases to breast cancer cases. The central regions in both genes, proposed to be associated with an increased ovarian:breast cancer ratio by
Thompson and Easton (2001, 2002), are marked. Furthermore, the distribution of breast (brca) and ovarian cancers (ovca) in families according to the site of
BRCA1 and BRCA2 mutations are indicated. (
a) Differences in risk of ovarian cancer were statistically significant for BRCA1 50 vs central portion (P¼0.027)
and BRCA2 50 vs central portion (P¼0.038). (
b) Differences in relative risks of ovarian vs breast cancer were statistically significant for BRCA2 50 vs central
portion (P¼0.017).
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spatients (71 mutations in 291 unrelated families (24.4%) and four
mutations in 58 sporadic patients (6.9%); P¼0.003). In breast–
ovarian cancer families, mutation frequencies were significantly
higher than in breast cancer-only families: 44.8% (30/67) vs 18.3%
(41/224) (Po0.0001) (Table 2). The highest mutation detection
ratio was obtained in breast–ovarian cancer families fulfilling the
criteria for hereditary disease (75%¼21/28), decreasing to 23.1%
(9/39) in families with familial breast and ovarian cancer
(Po0.0001). In breast cancer-only families, mutation frequencies
were 23.8% (15/63) and 16.1% (26/161) in families with,
respectively, hereditary and familial breast cancer (P¼0.185).
Especially, BRCA1 mutations conferred an increased risk for
ovarian cancer: on average, there were nearly three times as many
ovarian cancers in BRCA1 families than in BRCA2 families (0.89 vs
0.32; P¼0.091). The average number of breast cancer cases was
comparable (3.70 in BRCA1 and 3.72 in BRCA2 families; P¼0.965).
The ratio of ovarian to breast cancers was on average 0.41:1 for
BRCA1 families and 0.07:1 for BRCA2 families (P¼0.015).
A male breast cancer case was indicative of a BRCA2 mutation
segregating in the family (P¼0.002) (Table 1). Furthermore, a
relative with multiple primary breast cancers also increased the
chance for finding a BRCA mutation: in 26 of 66 families (39.4%)
with at least one relative diagnosed with multiple primary breast
cancers, a mutation was identified compared to 45 mutations in
225 families (20%) without such a phenotype (P¼0.002).
The mean age of diagnosis (7standard deviation) of the first
female breast cancer was 45.87 (712.80) years in mutation carriers
and 49.01 (712.35) years for persons without known mutations
(P¼0.001). On average, the age of onset was younger in BRCA1
compared to BRCA2 families; however, differences were not
statistically significant (44.82712.39 vs 48.00713.42 years;
P¼0.086). For the mean age of diagnosis of ovarian or male
breast cancer, no significant differences were obtained between
mutation-positive and mutation-negative families (data not
shown).
In total, four mutations were identified in 58 sporadic patients
fulfilling our inclusion criteria (Table 3). Three mutations (BRCA1
IVS5þ3A4G, 2626–2627delAA and BRCA2 6503–6504delTT)
were found in 41 sporadic patients with early-onset breast cancer
and one mutation (BRCA1 E1221X) in two sporadic patients
diagnosed with both breast and ovarian cancer. No mutations were
found in six sporadic patients with multiple primary breast
cancers, neither in five sporadic ovarian cancer patients with early-
onset disease nor in four sporadic males with breast cancer.
Variation in cancer risk by mutation position
In our series of families, we found an increased ovarian to breast
cancer ratio in the 50-end of both genes. Figure 1 suggests that, for
mutations 50 of BRCA1 exon 11, this may result from both an
increase in ovarian cancer risk and a reduction in breast cancer
risk. Differences in breast cancer risk were not statistically
significant. Also, for mutations in the 50 region of BRCA2,a
statistically significant increased incidence of ovarian cancer was
observed relative to the central portion of the gene. However, our
observations are based on a limited number of distinct mutations.
For BRCA2, an ‘Ovarian Cancer Cluster Region’ (OCCR) in the
middle third of the gene was proposed by Gayther et al (1997).
Surprisingly, in our study no ovarian cancer cases were recorded
Figure 2 RT–PCR was performed with primers spanning exons 11–15
of the BRCA2 gene (nucleotides 6948–7714; GenBank accession number
NM_000059) on RNA extracted from lymphocytes as described by Claes
et al (2003). RT–PCR on RNA from the patient carrying BRCA2 R2336H
(lane 1) showed a full-length fragment of 767bp and three faster migrating
bands (697bp: skipping of out of frame exon 13 (stop 2345); 671bp:
skipping of in-frame exon 12 (deletion of 32 amino acids); 601bp: skipping
of out of frame exons 12 and 13 (stop 2311)). In healthy control persons
(lanes 2 and 3), besides the full-length fragment, a band (671bp)
representing the skipping of in-frame exon 12, was also observed. M,
marker.
Table 2 Overview of all HBOC and FBOC families investigated and mutation detection frequencies
FBOC HBOC
# mutations found (%) # mutations found (%)
Phenotypes N BRCA1 BRCA2 BRCA N BRCA1 BRCA2 BRCA
Breast–ovarian cancer No male breast cancer patient 39 9 (23.1%) 0 9 (23.1%) 25 13 (52.0%) 6 (24.0%) 19 (76.0%)
families At least one male breast cancer patient 0 0 0 0 3 0 2 (66.7%) 2 (66.7%)
Total 39 9 (23.1%) 0 9 (23.1%) 28 13 (46.4%) 8 (28.6%) 21 (75.0%)
Breast cancer-only No male breast cancer patient 155 13 (8.4%) 11 (7.1%) 24 (15.5%) 60 11 (18.3%) 3 (5.0%) 14 (23.3%)
families At least one male breast cancer patient 6 0 2 (33.0%) 2 (33.0%) 3 0 1 (33.3%) 1 (33.0%)
Total 161 13 (8.1%) 13 (8.1%) 26 (16.1%) 63 11 (17.5%) 4 (6.3%) 15 (23.8%)
Total 200 22 (11.0%) 13 (6.5%) 35 (17.5%) 91 24 (26.4%) 12 (13.2%) 36 (39.6%)
FBOC¼familial breast and/or ovarian cancer; HBOC¼hereditary breast and/or ovarian cancer.
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OCCR.
DISCUSSION
We identified 75 disease-causing mutations in 349 Belgian breast/
ovarian cancer families selected for genetic testing. The prevalence
of BRCA1 mutations was approximately twice the prevalence of
BRCA2 mutations. Most strikingly, six mutations (BRCA1
IVS5þ3A4G, 2478–2479insG, E1221X, and BRCA2
IVS6þ1G4A, 6503–6504delTT and 9132delC) accounted for
nearly 60% of all mutations identified. BRCA1 2478–2479insG
and BRCA2 IVS6þ1G4A have not yet been reported in other
populations. BRCA1 IVS5þ3A4G is a Belgian founder mutation
that has also been found in a few German, Dutch and French
families (Claes et al,in preparation). BRCA1 E1221X and BRCA2
6503–6504delTT & 9132delC have been reported in several
populations worldwide (BIC database). Given the proportion of
all breast/ovarian cancer families in our population attributable to
recurring mutations, a cost-effective stepwise molecular screening
strategy of BRCA1 and BRCA2 may be applied in the future. A
first-stage analysis, covering the recurrent mutations, can be
offered to a substantial number of families, then, if a negative test
result is obtained, more stringent risk criteria can be applied for
complete analysis of the genes. Further examples of founder
mutations in particular regions of Belgium may be found; the
majority of the patients we analysed are living in North-West
Belgium. Therefore, larger studies are required.
Despite the fact that Belgians historically have been in contact
with many populations, only a limited number of founder
mutations from other countries were detected. BRCA1 5382insC,
an Ashkenazi Jewish founder mutation and the most frequent
mutation in many European populations, was identified in only
one Belgian family. Besides BRCA1 5382insC, no other Jewish
mutations were detected in our patient population. The deletion of
BRCA1 exon 22, the most recurrent Dutch mutation, was identified
in one Belgian patient with a Dutch mother. The BRCA1 exon 13 6-
kb duplication, a mutation likely to be derived from a British
ancestor (The BRCA1 Exon 13 Duplication Screening group, 2000),
was found once. Besides these two rearrangements, no other
mutations involving one or more exons were detected with MLPA
in all 55 remaining uninformative HBOC families, in 52 FBOC
families and 10 sporadic patients in whom no mutations were
identified with conventional PCR-based techniques. These pre-
liminary data suggest that genomic rearrangements in BRCA1 do
not have a major contribution in Belgian breast/ovarian cancer
families. However, as indicated before, we mainly screened
patients living in North-West Belgium; in other regions, this kind
of mutations may be more prevalent.
Besides true pathogenic mutations, we identified several
‘unclassified variants’. Many of them were identified in high-risk
families and occurred at amino acids that display substantial
evolutionary conservation. Some of them were likely to be
polymorphic for various reasons (Table 1). Most of the
unclassified variants in our study were infrequent in our
population and not reported before. A very high number of
properly selected control individuals would be needed to search
for statistically significant associations of these alleles with breast/
ovarian cancer. We recently started LOH analysis for several
variants to test the presumed association with the BRCA loci. We
are also investigating if some of the unclassified variants affect
correct splicing by disrupting functional exonic splicing enhancer
sequences, as described for a BRCA2 amino-acid substitution
(Fackenthal et al, 2002).
Our study permits to estimate the prevalence of BRCA1 and
BRCA2 mutations in a Belgian patient population referred to a
family cancer clinic. In 24.4% of the patients with a family history
of breast/ovarian cancer, a mutation was identified. In families
with at least one relative with ovarian cancer (Po0.0001), multiple
primary breast cancers (P¼0.002) or male breast cancer
(P¼0.002) significantly more mutations were identified compared
to families without such phenotypes (Table 2). The literature is not
unanimous about the predictive value of multiple primary
(ipsilateral or contralateral) breast cancers for finding a mutation.
Our results are in agreement with the studies of Bergthorsson et al
(2001), de la Hoya et al (2002) and Ford et al (1998); however,
others failed to demonstrate such a predictive value (Couch et al,
1997; Steinmann et al, 2001). Male breast cancer in combination
with a family history of breast/ovarian cancer was indicative of
finding a BRCA2 mutation (P¼0.002), which is consistent with a
recent population-based British study (Basham et al, 2002). In
none of the four Belgian sporadic male breast cancer patients a
mutation was identified. However, BRCA2 mutation prevalence in
sporadic male breast cancer has been found to be as high as 33 and
21% in the Hungarian and Swedish population (Haraldsson et al,
1998; Csokay et al, 1999). Larger studies in Belgian patients are
required before definite conclusions about mutation frequencies in
this group can be drawn.
In mutation-negative families, the average age of onset of female
breast cancer, but not male breast cancer, tended to be higher than
in families in whom a mutation was identified. The mean age of
Table 3 Phenotypical features of sporadic patients investigated (N¼58)
BRCA1 mutation-positive
patients
BRCA2 mutation-positive
patients
Mutation positive
patients
N%N% N %
41 female breast cancer patients (mean Dx 33.5,
median Dx 33, range 26–52)
2 4.9 1 2.4 3 7.3
Six patients with multiple primary breast cancers
(bilateral or multifocal) (mean Dx first breast cancer
39.8, median Dx 39.5, range 31–50)
000 0 0 0
Five ovarian cancer patients (mean Dx 35.4, median
Dx35, range 25–52)
000 0 0 0
Two patients with both primary breast and ovarian
cancer (mean Dx breast cancer 52.5 (range 50–
55); mean Dx ovarian cancer 50 (range 47–53)
15 0 0 01 5 0
Four male breast cancer patients (mean Dx 49.3,
median Dx 58.5, range 12–68)
000 0 0 0
58 sporadic patients 3 5.2 1 1.7 4 6.9
Dx¼age at diagnosis (years).
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mutation-negative families. These observations are in agreement
with large studies on ovarian cancer patients (Risch et al, 2001;
Frank et al, 2002). It has repeatedly been shown that only a small
percentage of BRCA-positive ovarian cancer cases occur at ages
o40 years (Boyd et al, 2000; Liede et al, 2002).
As early onset breast/ovarian cancer and the occurrence of
multiple primary breast and/ovarian cancers in a single individual
adds considerably to the prior probability of a mutation being
present, we evaluated the prevalence of BRCA1/2 mutations in
patients with these clinical characteristics and no further family
history. Three recurrent mutations (BRCA1 E1221X &
IVS5þ3A4G and BRCA2 6503–6504delTT) and one novel
mutation (BRCA1 2626–2627delAA) in 54 such patients were
identified. For the recurrent mutations, a de novo event was highly
unlikely. Haplotype analysis had revealed identical alleles with
other Belgian patients carrying BRCA1 E1221X and IVS5þ3A4G,
respectively (data not shown). The patient with the BRCA2 6503–
6504delTT mutation was bearing in addition two downstream
polymorphisms (IVS24-16T4C and K3326X) that had been
observed in all our other patients carrying the BRCA2 6503–
6504delTT mutation. BRCA1 2626–2627delAA has not yet been
reported in the BIC database and was identified in a sporadic patient
diagnosed with breast cancer at the age of 27 years. A de novo event
could not be ruled out as DNA of the parents was not (yet) available.
In only 7.5% of the sporadic patients diagnosed with breast
cancer at young age, BRCA1/2 mutations were identified. We
hypothesise a possible role for genetic variants in DNA double-
strand break repair genes in this patient group, since a significant
proportion of these patients showed elevated chromosomal
radiosensitivity by in vitro assays (Baeyens et al, 2002).
In hereditary breast cancer-only families, mutation detection
ratios were low (23.8%) compared to hereditary breast–ovarian
cancer families (75%) (Po0.0001). Mutation frequencies did not
statistically significantly differ between breast cancer-only families
with and without an autosomal dominant inheritance pattern of
the disease (23.8 vs 16.1%; P¼0.085). As breast cancer is relatively
frequent in Belgium, familial clustering of breast cancer may have
occurred by chance in some families. In a few families, mutations
undetectable by the techniques used may be present (e.g.
regulatory mutations) or some of the genetic variants reported
as being of ‘uncertain significance’ may be characterised as
deleterious in the future. Nevertheless, our findings strongly
suggest a role for additional breast cancer susceptibility genes.
From a clinical perspective, it would be most interesting to gain
an insight into a possible relationship between mutation site and
relative risk of breast or ovarian cancer. We found that in families
with mutations occurring 50 of BRCA1 exon 11 on average a
significantly higher number of ovarian cancers were present than
in families with mutations in the central portion of the gene
(Figure 1). This trend is not consistent with the study of The Breast
Cancer Linkage Consortium (BCLC) (Thompson and Easton, 2002)
reporting an increased ovarian to breast cancer ratio in the central
region of BRCA1 due to a lower breast cancer risk. Furthermore,
they found a reduced ovarian cancer risk associated with
mutations in the 30 part of the gene, a trend that was not observed
in our study.
For BRCA2, the BCLC study (Thompson and Easton, 2001)
revealed an increased ovarian to breast cancer ratio for OCCR
mutations, due to a reduced absolute risk of breast cancer. This
observation was not confirmed in our study population. In none of
our families bearing a BRCA2 OCCR mutation ovarian cancer was
part of the phenotypes. Several other investigators (for instance,
Frank et al, 1998; Ikeda et al, 2001; de la Hoya et al, 2002) also
failed to demonstrate an increased incidence of ovarian cancer in
the BRCA2 OCCR. In our study, mutations occurring 50 of the
OCCR were significantly associated with a higher ovarian cancer
risk relative to the central portion of the gene.
As the data from different studies are not consistent, we think
that associations between mutation position and phenotype are
not sufficiently strong to influence genetic counselling and
management of individual families. It is well known that large
variations in cancer risks are also observed in families bearing the
same mutation, suggesting the involvement of genetic and/or
environmental modifiers. For counselling of affected families, it
may be wiser to take into account the previous history of the
family.
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